



Toxopheresis

STUDIES

- Transmedac Innovations AG. Assessment, consultation and advisory board on research with therapeutic apheresis (DFPP) and its effects on environmental toxins, lipids and inflammation. Baar (CH): Transmedac Innovations AG; 2025.
- Burgard H. Clinical remission after therapeutic apheresis in a patient suffering from long term myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): a case report. Int Med Case Rep J. 2024 Dec 6;17:997–1002. doi:10.2147/IMCRJ.S476044.
- Korth J, Steenblock C, Walther R, Barbir M, Husung M, Velthof A. A single-center pilot study of therapeutic apheresis in patients with severe post-COVID syndrome. Horm Metab Res. 2024 Dec;56(12):869–874. doi:10.1055/a-2445-8593. Epub 09 Dec 2024.
- Transmedac Innovations AG. Profiling of patients with and without cardiovascular complication and inflammation and genetic profiling under therapeutic apheresis. Baar (CH): Transmedac Innovations AG; 2025
- Transmedac Innovations AG. Interim report for the 2nd contractual year 2025: Research on double filtration plasmapheresis (DFPP) and its effects on the aging process. Baar (CH): Transmedac Innovations AG; 2025 Jan.
- Transmedac Innovations AG. Final report 2: The effect of extracorporeal apheresis on Alzheimer's disease: how blood affects the brain. Baar (CH): Transmedac Innovations AG; 2026 Jan.
- Transmedac Innovations AG. Comparison of immunoadsorption with therapeutic apheresis (DFPP) with medium/small filter systems. Baar (CH): Transmedac Innovations AG; 2025 Mar. Project duration: 1 year.

STUDIES

- Nacul L, Authier FJ, Scheibenbogen C, et al. European Network on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (EUROMENE): expert consensus on the diagnosis, service provision, and care of people with ME/CFS in Europe. *Medicina*. 2021;57(5):510. doi:10.3390/medicina57050510
- Nacul LC, Lacerda EM, Pheby D, et al. Prevalence of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) in three regions of England: a repeated cross-sectional study in primary care. *BMC Med*. 2011;9:91. doi:10.1186/1741-7015-9-91
- Estévez-López F, Castro-Marrero J, Wang X, et al. Prevalence and incidence of myalgic encephalomyelitis/chronic fatigue syndrome in Europe-the Euro-epiME study from the European network EUROMENE: a protocol for a systematic review. *BMJ Open*. 2018;8(9):e020817. doi:10.1136/bmjopen-2017-020817
- Tschopp R, König RS, Rejmer P, Paris DH. Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): a preliminary survey among patients in Switzerland. *Heliyon*. 2023;9(5):e15595. doi:10.1016/j.heliyon.2023.e15595
- Hickie I, Davenport T, Wakefield D, et al. Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens: prospective cohort study. *BMJ*. 2006;333(7568):575. doi:10.1136/bmj.38933.585764.AE
- VanElzakker MB. Chronic fatigue syndrome from vagus nerve infection: a psychoneuroimmunological hypothesis. *Med Hypotheses*. 2013;81(3):414–423. doi:10.1016/j.mehy.2013.05.034
- Glassford JAG. The neuroinflammatory etiopathology of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). *Front Physiol*. 2017;8:88. doi:10.3389/fphys.2017.00088
- Clayton EW. Beyond myalgic encephalomyelitis/chronic fatigue syndrome: an IOM report on redefining an illness. *JAMA*. 2015;313(11):1101–1102. doi:10.1001/jama.2015.1346

Toxopheresis

STUDIES

- Katz BZ, Shiraishi Y, Mears CJ, Binns HJ, Taylor R. Chronic fatigue syndrome after infectious mononucleosis in adolescents. *Pediatrics*. 2009;124(1):189–193. doi:10.1542/peds.2008-1879
- Loebel M, Grabowski P, Heidecke H, et al. Antibodies to β adrenergic and muscarinic cholinergic receptors in patients with chronic fatigue syndrome. *Brain Behav Immun*. 2016;52:32–39. doi:10.1016/j.bbi.2015.09.013
- Tanaka S, Kuratsune H, Hidaka Y, et al. Autoantibodies against muscarinic cholinergic receptor in chronic fatigue syndrome. *Int J Mol Med*. 2003;12(2):225–230.
- Scheibenbogen C, Loebel M, Freitag H, et al. Immunoadsorption to remove β 2 adrenergic receptor antibodies in Chronic Fatigue Syndrome CFS/ME. *PLoS One*. 2018;13(3):e0193672. doi:10.1371/journal.pone.0193672
- Tölle M, Freitag H, Antelmann M, et al. Myalgic encephalomyelitis/chronic fatigue syndrome: efficacy of repeat immunoadsorption. *J Clin Med*. 2020;9(8):2443. doi:10.3390/jcm9082443
- Achleitner M, Steenblock C, Dänhardt J, et al. Clinical improvement of Long-COVID is associated with reduction in autoantibodies, lipids, and inflammation following therapeutic apheresis. *Mol Psychiatry*. 2023;28:1–6. doi:10.1038/s41380-023-02084-1
- Freitag H, Szklarski M, Lorenz S, et al. Autoantibodies to vasoregulative G-protein-coupled receptors correlate with symptom severity, autonomic dysfunction and disability in myalgic encephalomyelitis/chronic fatigue syndrome. *J Clin Med*. 2021;10(16):3675. doi:10.3390/jcm10163675
- Cervia-Hasler C, Brüningk SC, Hoch T, et al. Persistent complement dysregulation with signs of thromboinflammation in active long covid. *Science*. 2024;383(6680):eadg7942. doi:10.1126/science.adg7942
- Dalakas MC, Alexopoulos H, Spaeth PJ. Complement in neurological disorders and emerging complement-targeted therapeutics. *Nat Rev Neurol*. 2020;16(11):601–617. doi:10.1038/s41582-020-0400-0

Toxopheresis

STUDIES

- Park JW, Park BJ, Lee JS. et al. Systematic review of fatigue severity in ME/CFS patients: insights from randomized controlled trials. J Transl Med 2024; 22: 529
- Scheibenbogen C, Loebel M, Freitag H. et al. Immunoadsorption to remove ss2 adrenergic receptor antibodies in Chronic Fatigue Syndrome CFS/ME. PLoS One 2018; 13: e0193672
- Bornstein SR, Voit-Bak K, Donate T. et al. Chronic post-COVID-19 syndrome and chronic fatigue syndrome: is there a role for extracorporeal apheresis?. Mol Psychiatry 2022; 27: 34-37
- Seibert FS, Stervbo U, Wiemers L. et al. Severity of neurological Long-COVID symptoms correlates with increased level of autoantibodies targeting vasoregulatory and autonomic nervous system receptors. Autoimmun Rev 2023; 22: 103445
- Steenblock C, Toepfner N, Kok YP. et al. A multimodal approach for treating post-acute infectious syndrome. Brain Med 2024; 1: 1-7
- Chen C, Haupt SR, Zimmermann L. et al. Global prevalence of post-coronavirus disease 2019 (COVID-19) condition or long COVID: a meta-analysis and systematic review. J Infect Dis 2022; 226: 1593-1607
- Steenblock C, Walther R, Tselmin S. et al. Post COVID and apheresis – where are we standing?. Horm Metab Res 2022; 54: 715-720
- Davis HE, Assaf GS, McCorkell L. et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine 2021; 38: 101019
- Loebel M, Grabowski P, Heidecke H. et al. Antibodies to beta adrenergic and muscarinic cholinergic receptors in patients with chronic fatigue syndrome. Brain Behav Immun 2016; 52: 32-39

Toxopheresis

STUDIES

- Sotzny F, Blanco J, Capelli E. et al. Myalgic encephalomyelitis/chronic fatigue syndrome – evidence for an autoimmune disease. *Autoimmun Rev* 2018; 17: 601-609
- Asadi-Pooya AA, Akbari A, Emami A. et al. Risk factors associated with long COVID syndrome: a retrospective study. *Iran J Med Sci* 2021; 46: 428-436
- Ohkubo A, Okado T. Selective plasma exchange. *Transfus Apher Sci* 2017; 56: 657-660
- Fluge Ø, Risa K, Lunde S. et al. B-Lymphocyte depletion in myalgic encephalopathy/chronic fatigue syndrome. An open-label phase II study with rituximab maintenance treatment. *PLoS One* 2015; 10: e0129898
- Carruthers BM, van de Sande MI, De Meirleir KL. et al. Myalgic encephalomyelitis: International Consensus Criteria. *J Intern Med* 2011; 270: 327-338
- Achleitner M, Steenblock C, Danhardt J. et al. Clinical improvement of long-COVID is associated with reduction in autoantibodies, lipids, and inflammation following therapeutic apheresis. *Mol Psychiatry* 2023; 28: 2872-2877
- Gizzas B, Reuken PA, Katzer K. et al. Immunoadsorption to treat patients with severe post-COVID syndrome. *Ther Apher Dial* 2023; 27: 790-801
- Tolle M, Freitag H, Antelmann M. et al. Myalgic encephalomyelitis/chronic fatigue syndrome: efficacy of repeat immunoadsorption. *J Clin Med* 2020; 9: 2443
- Stein E, Heindrich C, Wittke K. et al. Observational study of repeat Immunoadsorption (RIA) in post-COVID ME/CFS patients with elevated ss2-adrenergic receptor autoantibodies – an interim report. *J Clin Med* 2023; 12: 6428

Toxopheresis

STUDIES

- Stein E, Heindrich C, Wittke K. et al. Efficacy of repeat immunoadsorption in post-COVID ME/CFS patients with elevated B2-adrenergic receptor autoantibodies: a prospective cohort study <https://ssrncom/abstract=4911576> 2024
- Lai YJ, Liu SH, Manachevakul S. et al. Biomarkers in long COVID-19: a systematic review. Front Med (Lausanne) 2023; 10: 1085988
- Tsilingiris D, Vallianou NG, Karampela I. et al. Laboratory findings and biomarkers in long COVID: what do we know so far? Insights into epidemiology, pathogenesis, therapeutic perspectives and challenges. Int J Mol Sci 2023; 24: 10458
- Yin JX, Agbana YL, Sun ZS. et al. Increased interleukin-6 is associated with long COVID-19: a systematic review and meta-analysis. Infect Dis Poverty 2023; 12: 43
- Hatano Y, Katagiri K, Arakawa S. et al. Successful treatment by double-filtration plasmapheresis of a patient with bullous pemphigoid: effects in vivo on transcripts of several genes for chemokines and cytokines in peripheral blood mononuclear cells. Br J Dermatol 2003; 148: 573-579
- Bensing J. Bridging the gap. The separate worlds of evidence-based medicine and patient-centered medicine. Patient Educ Couns 2000; 39: 17-25

Toxopheresis

PUBLICATIONS

Husung M, Burgard HM. Gesundheit neu gedacht: Therapie und Prävention im Einklang. Taschenbuch, erschienen 25. November 2024. ISBN 979-8301225383.

Burgard HM, Husung M. A New Perspective on Health: Where Therapy and Prevention Align. Hardcover, published 27 January 2026.

Burgard H. LONGEVITY – Gesund werden geht auch anders: How to identify and eliminate the causes of your illnesses. Paperback, published 4 September 2025.

Autologous blood serum therapy

STUDIES

- Brancato SK, Albina JE: Wound macrophages as key regulators of repair: Origin, phenotype, and function. *Am J Pathol.* Elsevier Inc.; (2011);178(1):19–25.
- Nasirzade J et al.: Platelet-rich fibrin elicits an anti-inflammatory response in macrophages in vitro. *J Periodontol.* (2019):JPER.19-0216. PMID: 31376159
- West MD, Sternberg H, Labat I, Janus J, Chapman KB, Malik NN, de Grey AD, Larocca D: Toward a unified theory of aging and regeneration. *Regen Med.* 2019;14(9):867–886. PMID: 31455183
- Baltzer AWA et al.: Autologous conditioned serum (Orthokine®) is an effective treatment for knee osteoarthritis. *Osteoarthritis and Cartilage* (2009) 17(2):152–160
- Becker C et al.: Efficacy of epidural perineural injections with autologous conditioned serum for lumbar radicular compression: an investigator-initiated, prospective, double-blind, reference-controlled study. *Spine* (2007) 32(17):1803–1808
- Baselga J et al.: Treatment of Osteoarthritis of the Knee with a Combination of Autologous Conditioned Serum and Physiotherapy: A Two-Year Observational Study. *PLoS ONE* (2015) 10(12): e0145551
- Shirokova K et al.: Intra-articular injections of a whole blood-clot secretome, autologous conditioned serum, have superior clinical and biochemical efficacy over platelet-rich plasma and induce rejuvenation-associated changes of joint metabolism. A prospective, controlled, open-label clinical study in knee osteoarthritis. *Rejuvenation Res.* (2019) Dec 17; rej.2019.2263. PMID: 31847701
- Landén NX et al.: Transition from inflammation to proliferation: a critical step during wound healing. *Cell Mol Life Sci.* (2016);73(20):3861–85. PMID: 27180275
- Wu Y-S, Chen S-N: Apoptotic cell: linkage of inflammation and wound healing. *Front Pharmacol.* (2014);5(January):1. PMID: 24478702
- Norris PC et al.: A cluster of immunoresolvents links coagulation to innate host defense in human blood. *Sci Signal.* (2017) Aug 1;10(490). PMID: 28765512
- Norris PC et al.: Resolution metabolomes activated by hypoxic environment. *Sci Adv.* (2019) Oct 23;5(10):eaax4895. PMID: 31681846
- Romano M et al.: Concise Review: Pro-Resolving Lipid Mediators and Receptors in Stem Cell Biology. *Stem Cells Transl Med.* (2019);sctm.19-0078
- Ishihara T et al.: Omega-3 fatty acid-derived mediators that control inflammation and tissue homeostasis. *Int Immunol.* (2019);31(9):559–567. PMID: 30772915
- Uhlén M et al.: The human secretome. *Sci Signal.* 2019 Nov 26;12(609):465815. PMID: 31772123
- Wehling P et al.: Autologous Conditioned Serum in the treatment of Orthopaedic diseases – The Orthokine® Therapy. *Biodrugs* (2007) 21(5):323–332
- Cell Division And Growth, *Encyclopedia Britannica*, <https://www.britannica.com/science/cell-biology/Cell-division-and-growth>
- Meijer H et al.: The production of anti-inflammatory cytokines in whole blood by physico-chemical induction. *Inflamm Res* (2003) 52(10):404–407
- Barrientos S et al.: Growth factors and cytokines in wound healing. *Wound Repair Regen.* (2008);16(5):585–601. PMID: 19128254
- Colombo M et al.: Biogenesis, Secretion, and Intercellular Interactions of Exosomes and Other Extracellular Vesicles. *Annu Rev Cell Dev Biol.* (2014);30(1):255–289
- Yang KG et al.: Autologous interleukin-1 receptor antagonist improves function and symptoms in osteoarthritis when compared to placebo in a prospective randomized controlled trial. *Osteoarthritis and Cartilage* (2008) 16(4):498–505
- Yang C, Robbins PD: Immunosuppressive Exosomes: A New Approach for Treating Arthritis. *Int J Rheumatol.* (2012);2012:1–8. PMID: 22548070
- Basil M, Levy B: Specialized pro-resolving mediators: endogenous regulators of infection and inflammation. *Nat Rev Immunol* 16, 51–67 (2016). <https://doi.org/10.1038/nri.2015.4>
- Norris PC et al.: A cluster of immunoresolvents links coagulation to innate host defense in human blood. *Sci Signal.* (2017) Aug 1;10(490). PMID: 28765512
- Blázquez R et al.: Conditioned Serum Enhances the Chondrogenic and Immunomodulatory Behavior of Mesenchymal Stem Cells. *Front Pharmacol.* 2019

